---
title: "Altamira Therapeutics (OTCQB: CYTOF) reports 2024 financial results, focuses on expanding RNA delivery technology."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/238284873.md"
description: "Bermuda-based Altamira Therapeutics Ltd. (OTCQB: CYTOF) announced its business update and disclosed its financial performance for the full year of 2024. Altamira focuses on developing and marketing RNA delivery technology for non-liver targets."
datetime: "2025-04-30T12:22:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/238284873.md)
  - [en](https://longbridge.com/en/news/238284873.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/238284873.md)
generator: "portal-rs"
---

# Altamira Therapeutics (OTCQB: CYTOF) reports 2024 financial results, focuses on expanding RNA delivery technology.

Bermuda-based Altamira Therapeutics Ltd. (OTCQB: CYTOF) announced its business update and disclosed its financial performance for the full year of 2024. Altamira focuses on developing and marketing RNA delivery technology for non-liver targets.

### Related Stocks

- [CYTOF.US](https://longbridge.com/en/quote/CYTOF.US.md)

## Related News & Research

- [Nordic Development Fund appoints Jatin Yadav as Climate Innovation Challenge Fund manager](https://longbridge.com/en/news/296777084.md)
- [Bavarian Nordic Q2 FY26 EBITDA margin widens 12 percentage points to 45%; revenue rises 23% to DKK 2.03 billion](https://longbridge.com/en/news/296572827.md)
- [Enersize hands Swedish compressed-air efficiency operations to ONE Nordic in 20% revenue-share deal](https://longbridge.com/en/news/296743761.md)
- [BAVA: Upgraded 2026 guidance after strong H1 revenue and profitability, led by Travel Health growth](https://longbridge.com/en/news/296572886.md)
- [Bavarian Nordic Upgrades its Full-Year 2026 Financial Guidance](https://longbridge.com/en/news/296572606.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**